<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font19 { font-size : 19; } .font21 { font-size : 21; } .font24 { font-size : 24; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">Phase </span>
   <span class="font24">patients </span>
   <span class="font21">study </span>
   <span class="font19">antibody </span>
   <span class="font19">treatment </span>
   <span class="font19">clinical </span>
   <span class="font18">IgG </span>
   <span class="font17">cancer </span>
   <span class="font16">therapeutics </span>
   <span class="font16">collab: </span>
   <span class="font15">studies </span>
   <span class="font15">review </span>
   <span class="font15">cell </span>
   <span class="font15">granted </span>
   <span class="font14">Humanized </span>
   <span class="font14">data </span>
   <span class="font14">results </span>
   <span class="font14">FDA </span>
   <span class="font14">(NCT) </span>
   <span class="font14">press </span>
   <span class="font14">primary </span>
   <span class="font14">release </span>
   <span class="font14">approval </span>
   <span class="font14">mAb </span>
   <span class="font14">phase </span>
   <span class="font14">regulatory </span>
   <span class="font13">migraine </span>
   <span class="font13">advanced </span>
   <span class="font13">response </span>
   <span class="font13">Human </span>
   <span class="font13">rate </span>
   <span class="font13">efficacy </span>
   <span class="font13">placebo </span>
   <span class="font13">BLA </span>
   <span class="font13">Drug </span>
   <span class="font13">mAbs </span>
   <span class="font12">marketing </span>
   <span class="font12">evaluated </span>
   <span class="font12">success </span>
   <span class="font12">undergoing </span>
   <span class="font12">approved </span>
   <span class="font12">compared </span>
   <span class="font12">safety </span>
   <span class="font12">antibodies </span>
   <span class="font12">days </span>
   <span class="font12">development </span>
   <span class="font12">humanized </span>
   <span class="font12">late-stage </span>
   <span class="font12">rates </span>
   <span class="font12">disease </span>
   <span class="font12">therapy </span>
   <span class="font12">{border-style </span>
   <span class="font12">November </span>
   <span class="font12">cancer, </span>
   <span class="font12">combination </span>
   <span class="font12">number </span>
   <span class="font12">ADC </span>
   <span class="font12">lymphoma </span>
   <span class="font12">overall </span>
   <span class="font12">px;} </span>
   <span class="font12">trial </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">Novartis </span>
   <span class="font12">Orphan </span>
   <span class="font12">vedotin </span>
   <span class="font11">PD- </span>
   <span class="font11">application </span>
   <span class="font11">growth </span>
   <span class="font11">immune </span>
   <span class="font11">including </span>
   <span class="font11">administered </span>
   <span class="font11">completion </span>
   <span class="font11">drug </span>
   <span class="font11">lung </span>
   <span class="font11">metastatic </span>
   <span class="font11">previously </span>
   <span class="font11">chronic </span>
   <span class="font11">complete </span>
   <span class="font11">designation </span>
   <span class="font11">included </span>
   <span class="font11">non-cancer </span>
   <span class="font11">versus </span>
   <span class="font11">European </span>
   <span class="font11">Reichert </span>
   <span class="font11">available </span>
   <span class="font11">based </span>
   <span class="font11">carcinoma </span>
   <span class="font11">date </span>
   <span class="font11">receptor </span>
   <span class="font11">study, </span>
   <span class="font11">treated </span>
   <span class="font11">watch </span>
   <span class="font11">(NCT), </span>
   <span class="font11">MAbs. </span>
   <span class="font11">baseline </span>
   <span class="font11">designations </span>
   <span class="font11">entered </span>
   <span class="font11">evaluation </span>
   <span class="font11">factor </span>
   <span class="font11">human </span>
   <span class="font11">include </span>
   <span class="font11">indications </span>
   <span class="font11">received </span>
   <span class="font11">refractory </span>
   <span class="font11">sponsored </span>
   <span class="font11">targeting </span>
   <span class="font11">Administration </span>
   <span class="font11">FDA’s </span>
   <span class="font11">Figure </span>
   <span class="font11">HIV </span>
   <span class="font11">Lilly </span>
   <span class="font11">September </span>
   <span class="font11">adults </span>
   <span class="font11">approvals </span>
   <span class="font11">commercial </span>
   <span class="font11">dose </span>
   <span class="font11">fewer </span>
   <span class="font11">pain </span>
   <span class="font11">randomized </span>
   <span class="font11">relapsed </span>
   <span class="font11">reported </span>
   <span class="font11">time </span>
   <span class="font11">weeks </span>
   <span class="font11">&amp;lt; </span>
   <span class="font11">Alder </span>
   <span class="font11">Antibodies </span>
   <span class="font11">Antibody </span>
   <span class="font11">Breakthrough </span>
   <span class="font11">Emgality </span>
   <span class="font11">July </span>
   <span class="font11">March </span>
   <span class="font11">PROMISE </span>
   <span class="font11">Therapeutics </span>
   <span class="font11">analysis </span>
   <span class="font11">announced </span>
   <span class="font11">announces </span>
   <span class="font11">anti-PD- </span>
   <span class="font11">authorization </span>
   <span class="font11">cancer. </span>
   <span class="font11">caplacizumab </span>
   <span class="font11">currently </span>
   <span class="font11">developed </span>
   <span class="font11">endpoint </span>
   <span class="font11">excluded. </span>
   <span class="font11">new </span>
   <span class="font11">patients. </span>
   <span class="font11">psoriasis </span>
   <span class="font11">reduction </span>
   <span class="font11">targets </span>
   <span class="font11">total </span>
   <span class="font11">transition </span>
   <span class="font11">year </span>
   <span class="font11">B-cell </span>
   <span class="font11">Data </span>
   <span class="font11">Fast </span>
   <span class="font11">Food </span>
   <span class="font11">MOR </span>
   <span class="font11">PFS </span>
   <span class="font11">bars, </span>
   <span class="font11">brolucizumab </span>
   <span class="font11">eptinezumab </span>
   <span class="font11">evaluating </span>
   <span class="font11">indicated </span>
   <span class="font11">plaque </span>
   <span class="font11">positive </span>
   <span class="font11">prevention </span>
   <span class="font11">product </span>
   <span class="font11">submission </span>
   <span class="font11">tanezumab </span>
   <span class="font11">therapeutic </span>
   <span class="font11">tildrakizumab </span>
   <span class="font11">trials </span>
   <span class="font11">watch’ </span>
   <span class="font10">.). </span>
   <span class="font10">Bio </span>
   <span class="font10">Hodgkin’s </span>
   <span class="font10">MMDs </span>
   <span class="font10">Roche </span>
   <span class="font10">Seattle </span>
   <span class="font10">Table </span>
   <span class="font10">Therapy </span>
   <span class="font10">Track </span>
   <span class="font10">Zhang </span>
   <span class="font10">article </span>
   <span class="font10">checkpoint </span>
   <span class="font10">episodic </span>
   <span class="font10">large </span>
   <span class="font10">leukemia </span>
   <span class="font10">molecule </span>
   <span class="font10">non-small </span>
   <span class="font10">pipeline </span>
   <span class="font10">polatuzumab </span>
   <span class="font10">priority </span>
   <span class="font10">px; </span>
   <span class="font10">quarter </span>
   <span class="font10">relapsed/refractory </span>
   <span class="font10">review. </span>
   <span class="font10">secondary </span>
   <span class="font10">studies, </span>
   <span class="font10">urothelial </span>
   <span class="font10">{font-family </span>
   <span class="font10">-week </span>
   <span class="font10">./.. </span>
   <span class="font10">AbbVie </span>
   <span class="font10">Nobel </span>
   <span class="font10">Pharmaceuticals </span>
   <span class="font10">Sesen </span>
   <span class="font10">TSR- </span>
   <span class="font10">UCB </span>
   <span class="font10">Wang </span>
   <span class="font10">adult </span>
   <span class="font10">binds </span>
   <span class="font10">biologics </span>
   <span class="font10">companies </span>
   <span class="font10">death </span>
   <span class="font10">disease. </span>
   <span class="font10">display </span>
   <span class="font10">doses </span>
   <span class="font10">font-size </span>
   <span class="font10">known </span>
   <span class="font10">low </span>
   <span class="font10">mean </span>
   <span class="font10">median </span>
   <span class="font10">monthly </span>
   <span class="font10">multiple </span>
   <span class="font10">osteoarthritis </span>
   <span class="font10">phage </span>
   <span class="font10">preventive </span>
   <span class="font10">programmed </span>
   <span class="font10">respectively. </span>
   <span class="font10">response, </span>
   <span class="font10">solely </span>
   <span class="font10">therapy. </span>
   <span class="font10">-month </span>
   <span class="font10">Amgen </span>
   <span class="font10">Biopharmaceuticals </span>
   <span class="font10">China </span>
   <span class="font10">Chinese </span>
   <span class="font10">Clinical </span>
   <span class="font10">EU. </span>
   <span class="font10">Eli </span>
   <span class="font10">Hay </span>
   <span class="font10">IL- </span>
   <span class="font10">Kyowa </span>
   <span class="font10">Takhzyro </span>
   <span class="font10">US, </span>
   <span class="font10">United </span>
   <span class="font10">aflibercept </span>
   <span class="font10">approves </span>
   <span class="font10">attacks </span>
   <span class="font10">breast </span>
   <span class="font10">candidates </span>
   <span class="font10">carcinoma, </span>
   <span class="font10">cells </span>
   <span class="font10">classified </span>
   <span class="font10">company </span>
   <span class="font10">complement </span>
   <span class="font10">double-blind, </span>
   <span class="font10">double; </span>
   <span class="font10">end </span>
   <span class="font10">endpoints </span>
   <span class="font10">enfortumab </span>
   <span class="font10">enter </span>
   <span class="font10">estimated </span>
   <span class="font10">experienced </span>
   <span class="font10">hepatocellular </span>
   <span class="font10">increased </span>
   <span class="font10">junction </span>
   <span class="font10">locally </span>
   <span class="font10">lymphoma. </span>
   <span class="font10">mAb, </span>
   <span class="font10">mg, </span>
   <span class="font10">moderate-to-severe </span>
   <span class="font10">mogamulizumab </span>
   <span class="font10">novel </span>
   <span class="font10">only. </span>
   <span class="font10">open-label, </span>
   <span class="font10">optica </span>
   <span class="font10">organizations </span>
   <span class="font10">outcome </span>
   <span class="font10">pivotal </span>
   <span class="font10">products </span>
   <span class="font10">progress </span>
   <span class="font10">quarterly </span>
   <span class="font10">rare </span>
   <span class="font10">scFv </span>
   <span class="font10">solid </span>
   <span class="font10">squamous </span>
   <span class="font10">study. </span>
   <span class="font10">ublituximab </span>
   <span class="font10">week </span>
   <span class="font10">August </span>
   <span class="font10">Chugai </span>
   <span class="font10">Co. </span>
   <span class="font10">Company </span>
   <span class="font10">December </span>
   <span class="font10">HER </span>
   <span class="font10">HIV- </span>
   <span class="font10">HLH </span>
   <span class="font10">Hengrui </span>
   <span class="font10">Inc.) </span>
   <span class="font10">Innovent </span>
   <span class="font10">Isatuximab </span>
   <span class="font10">MAbs </span>
   <span class="font10">Medicine </span>
   <span class="font10">MorphoSys </span>
   <span class="font10">PD-, </span>
   <span class="font10">PD-L </span>
   <span class="font10">Pharmaceutical </span>
   <span class="font10">Sanofi </span>
   <span class="font10">Smith </span>
   <span class="font10">Society </span>
   <span class="font10">Teprotumumab </span>
   <span class="font10">aTTP </span>
   <span class="font10">academic </span>
   <span class="font10">addition, </span>
   <span class="font10">additional </span>
   <span class="font10">bendamustine </span>
   <span class="font10">bladder </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">change </span>
   <span class="font10">checkpoints </span>
   <span class="font10">cohort </span>
   <span class="font10">combined </span>
   <span class="font10">completed </span>
   <span class="font10">cutaneous </span>
   <span class="font10">defined </span>
   <span class="font10">developing </span>
   <span class="font10">disease, </span>
   <span class="font10">disorders </span>
   <span class="font10">entering </span>
   <span class="font10">epithelial </span>
   <span class="font10">erenumab-aooe </span>
   <span class="font10">firms; </span>
   <span class="font10">fremanezumab </span>
   <span class="font10">government, </span>
   <span class="font10">immune-mediated </span>
   <span class="font10">immunotoxin </span>
   <span class="font10">inhibitor </span>
   <span class="font10">intended </span>
   <span class="font10">key </span>
   <span class="font10">lower </span>
   <span class="font10">measures </span>
   <span class="font10">molecules </span>
   <span class="font10">months </span>
   <span class="font10">moxetumomab </span>
   <span class="font10">near </span>
   <span class="font10">non-profit </span>
   <span class="font10">partial </span>
   <span class="font10">participants </span>
   <span class="font10">patients, </span>
   <span class="font10">period. </span>
   <span class="font10">placebo, </span>
   <span class="font10">placebo-controlled, </span>
   <span class="font10">plus </span>
   <span class="font10">potential </span>
   <span class="font10">proteins </span>
   <span class="font10">provide </span>
   <span class="font10">purpura </span>
   <span class="font10">relapse </span>
   <span class="font10">respectively, </span>
   <span class="font10">review, </span>
   <span class="font10">risankizumab </span>
   <span class="font10">satralizumab </span>
   <span class="font10">second </span>
   <span class="font10">showed </span>
   <span class="font10">single </span>
   <span class="font10">small </span>
   <span class="font10">solid; </span>
   <span class="font10">submitted </span>
   <span class="font10">systemic </span>
   <span class="font10">tesirine </span>
   <span class="font10">that, </span>
   <span class="font10">therapeutics. </span>
   <span class="font10">thrombocytopenic </span>
   <span class="font10">thrombotic </span>
   <span class="font10">variety </span>
   <span class="font10">various </span>
   <span class="font10">women </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">‘Antibodies </span>
   <span class="font10">‘antibodies </span>
   <span class="font10">(%) </span>
   <span class="font10">(Phase </span>
   <span class="font10">-year </span>
   <span class="font10">.%, </span>
   <span class="font10">.), </span>
   <span class="font10">./..-T </span>
   <span class="font10">./mabs. </span>
   <span class="font10">Abbreviations: </span>
   <span class="font10">Alexion </span>
   <span class="font10">American </span>
   <span class="font10">April </span>
   <span class="font10">Astellas </span>
   <span class="font10">AstraZeneca/MedImmune </span>
   <span class="font10">Breast </span>
   <span class="font10">Burosumab </span>
   <span class="font10">CGRP </span>
   <span class="font10">CGRP, </span>
   <span class="font10">CSCC </span>
   <span class="font10">Camrelizumab </span>
   <span class="font10">Caplacizumab </span>
   <span class="font10">Chen </span>
   <span class="font10">Chimeric </span>
   <span class="font10">Co., </span>
   <span class="font10">CytoDyn </span>
   <span class="font10">DLBCL </span>
   <span class="font10">DLBCL. </span>
   <span class="font10">Diffuse </span>
   <span class="font10">EV- </span>
   <span class="font10">Enfortumab </span>
   <span class="font10">FDA. </span>
   <span class="font10">Genetics </span>
   <span class="font10">Genetics, </span>
   <span class="font10">HAE </span>
   <span class="font10">HARRIER </span>
   <span class="font10">HAWK </span>
   <span class="font10">HERCULES </span>
   <span class="font10">Hakko </span>
   <span class="font10">III </span>
   <span class="font10">International </span>
   <span class="font10">Jiangsu </span>
   <span class="font10">Kirin </span>
   <span class="font10">LLC </span>
   <span class="font10">Liu </span>
   <span class="font10">Medicines </span>
   <span class="font10">Melanoma </span>
   <span class="font10">October </span>
   <span class="font10">PFS. </span>
   <span class="font10">Patients </span>
   <span class="font10">Pfizer </span>
   <span class="font10">Pharma </span>
   <span class="font10">Priority </span>
   <span class="font10">Results </span>
   <span class="font10">Satralizumab </span>
   <span class="font10">Spartalizumab </span>
   <span class="font10">T-cell </span>
   <span class="font10">Ulcerative </span>
   <span class="font10">Union </span>
   <span class="font10">VISTA </span>
   <span class="font10">X-linked </span>
   <span class="font10">Yang </span>
   <span class="font10">accelerated </span>
   <span class="font10">acquired </span>
   <span class="font10">activity </span>
   <span class="font10">adenocarcinoma </span>
   <span class="font10">adhesion </span>
   <span class="font10">angioedema </span>
   <span class="font10">announce </span>
   <span class="font10">anti-cancer </span>
   <span class="font10">antibody-drug </span>
   <span class="font10">anticipated </span>
   <span class="font10">average, </span>
   <span class="font10">background </span>
   <span class="font10">binding </span>
   <span class="font10">blocks </span>
   <span class="font10">bold </span>
   <span class="font10">calcitonin </span>
   <span class="font10">cells. </span>
   <span class="font10">chemokine </span>
   <span class="font10">chemotherapy </span>
   <span class="font10">composed </span>
   <span class="font10">conducted </span>
   <span class="font10">conjugated </span>
   <span class="font10">corporate </span>
   <span class="font10">courier; </span>
   <span class="font10">dates </span>
   <span class="font10">diffuse </span>
   <span class="font10">directed </span>
   <span class="font10">domain </span>
   <span class="font10">dosing </span>
   <span class="font10">drugs </span>
   <span class="font10">duocarmazine </span>
   <span class="font10">em; </span>
   <span class="font10">evaluate </span>
   <span class="font10">events </span>
   <span class="font10">expansion </span>
   <span class="font10">expected </span>
   <span class="font10">fates </span>
   <span class="font10">fluid </span>
   <span class="font10">follow-up </span>
   <span class="font10">followed </span>
   <span class="font10">fusion </span>
   <span class="font10">gastric </span>
   <span class="font10">gene-related </span>
   <span class="font10">given </span>
   <span class="font10">govitecan </span>
   <span class="font10">history </span>
   <span class="font10">hypophosphatemia </span>
   <span class="font10">ibalizumab </span>
   <span class="font10">included. </span>
   <span class="font10">indications. </span>
   <span class="font10">infection </span>
   <span class="font10">invasive </span>
   <span class="font10">issued </span>
   <span class="font10">late </span>
   <span class="font10">license </span>
   <span class="font10">life-threatening </span>
   <span class="font10">macular </span>
   <span class="font10">monatox </span>
   <span class="font10">monoclonal </span>
   <span class="font10">multi-center, </span>
   <span class="font10">nAMD </span>
   <span class="font10">neuromyelitis </span>
   <span class="font10">non-muscle </span>
   <span class="font10">objective </span>
   <span class="font10">only, </span>
   <span class="font10">pain, </span>
   <span class="font10">pasudotox </span>
   <span class="font10">pediatric </span>
   <span class="font10">peptide </span>
   <span class="font10">placebo. </span>
   <span class="font10">plasma </span>
   <span class="font10">platelet </span>
   <span class="font10">postmenopausal </span>
   <span class="font10">prior </span>
   <span class="font10">progressed </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized, </span>
   <span class="font10">rate, </span>
   <span class="font10">recurrent </span>
   <span class="font10">regions </span>
   <span class="font10">relevant </span>
   <span class="font10">reports </span>
   <span class="font10">responses </span>
   <span class="font10">risk </span>
   <span class="font10">sickle </span>
   <span class="font10">significantly </span>
   <span class="font10">spectrum </span>
   <span class="font10">sponsoring </span>
   <span class="font10">standard </span>
   <span class="font10">substantial </span>
   <span class="font10">survival </span>
   <span class="font10">syndrome </span>
   <span class="font10">top-line </span>
   <span class="font10">tumor </span>
   <span class="font10">types </span>
   <span class="font10">untreated </span>
   <span class="font10">variable </span>
   <span class="font10">viral </span>
   <span class="font10">virus </span>
   <span class="font10">vs. </span>
   <span class="font10">weeks. </span>
   <span class="font10">years </span>
  </p>
 </body>
</html>
